Disparate Formulations for Machine Perfusion: A Survey of Organ Procurement Organizations' Medication Additives and Outcome Analyses

Exp Clin Transplant. 2021 Nov;19(11):1124-1132. doi: 10.6002/ect.2021.0037.

Abstract

Objectives: Machine perfusionfor kidney preservation is a common practice. There is no consensus on the best formula for perfusion solutions. We aimed to discern the additives that organ procurement organizations in the United States include in their perfusate and the impact of these additives on transplant outcomes.

Materials and methods: A telephone survey of all 58 organ procurement organizations in the United States regarding additives to their perfusion solutions was conducted. The survey data were merged with transplant recipient outcome data from the United Network for Organ Sharing database.The final analysis included perfused kidneys between January 2014 and March 2019. Logistic regressions were performed to investigate whether a particular perfusion formula was associated with delayed graft function, primary nonfunction, or early graft failure.

Results: Additives correlated with decreased rates of graft failure were mannitol in all kidneys and kidneys of lower quality (P < .01) and penicillin/ampicillin in all kidneys (P < .05). Additives associated with increased graft failure regardless of type included verapamil in all kidneys (P < .05) and kidneys of lower quality (P < .01) and arginine with glutathione in all kidneys and low-quality kidneys alone (P < .01).

Conclusions: Further outcomes research and standardized guidelines for additives in machine perfusion of kidneys across all organ procurement organizations are needed.

MeSH terms

  • Graft Survival
  • Humans
  • Kidney
  • Kidney Transplantation* / adverse effects
  • Organ Preservation / adverse effects
  • Perfusion / adverse effects
  • Tissue Donors
  • Tissue and Organ Procurement*
  • Treatment Outcome
  • United States